Compare PPCB & RELI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PPCB | RELI |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Specialty Insurers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 5.5M |
| IPO Year | N/A | N/A |
| Metric | PPCB | RELI |
|---|---|---|
| Price | $0.22 | $0.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 565.5K | ★ 852.0K |
| Earning Date | 02-15-2026 | 03-05-2026 |
| Dividend Yield | N/A | ★ 7.23% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $13,115,995.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.24 | $0.39 |
| 52 Week High | $145.46 | $3.55 |
| Indicator | PPCB | RELI |
|---|---|---|
| Relative Strength Index (RSI) | 27.01 | 33.25 |
| Support Level | $0.24 | $0.46 |
| Resistance Level | $0.40 | $0.55 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 7.08 | 9.24 |
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing acquisition strategies, initially and focused on wholesale and retail insurance agencies. Its primary strategies is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.